Search the MBS

Standard Search

Advanced Search Search Tips

Enter keywords or item numbers below
Search Options

Results 1 to 10 of 34 matches

Category 5 - DIAGNOSTIC IMAGING SERVICES

Capital Sensitivity Diagnostic Imaging Equipment

Category 5 - DIAGNOSTIC IMAGING SERVICES

Requests for R-type Diagnostic Imaging Services

Category 5 - DIAGNOSTIC IMAGING SERVICES

Group I2 - Computed Tomography (CT)

Category 5 - DIAGNOSTIC IMAGING SERVICES

Group I4 - Nuclear Medicine Imaging

Category 3 - THERAPEUTIC PROCEDURES

15559

15559 - Additional Information

Item Start Date:
01-May-2006
Description Updated:
01-May-2006
Schedule Fee Updated:
01-Jul-2019

Group
T2 - Radiation Oncology
Subgroup
5 - Computerised Planning

DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 2 COMPLEXITY where:

(a)    dosimetry for a two phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, two planning target volumes and one organ at risk defined in the prescription; or

(b)    dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and two organ at risk dose goals or constraints defined in the prescription; or

(c)    image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 1 complexity.


All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images



Fee: $880.40 Benefit: 75% = $660.30 85% = $795.70

(See para TN.2.3 of explanatory notes to this Category)

Category 3 - THERAPEUTIC PROCEDURES

15562

15562 - Additional Information

Item Start Date:
01-May-2006
Description Updated:
01-May-2006
Schedule Fee Updated:
01-Jul-2019

Group
T2 - Radiation Oncology
Subgroup
5 - Computerised Planning

DOSIMETRY FOR THREE DIMENSIONAL CONFORMAL RADIOTHERAPY OF LEVEL 3 COMPLEXITY - where:

(a)    dosimetry for a three or more phase three dimensional conformal treatment plan using CT image volume dataset(s) with at least one gross tumour volume, three planning target volumes and one organ at risk defined in the prescription; or

(b)    dosimetry for a two phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, and

        (i) two planning target volumes; or

        (ii) two organ at risk dose goals or constraints defined in the prescription.

or

(c)    dosimetry for a one phase three dimensional conformal treatment plan using CT image volume datasets with at least one gross tumour volume, one planning target volume and three organ at risk dose goals or constraints defined in the prescription;

or

(d)    image fusion with a secondary image (CT, MRI or PET) volume dataset used to define target and organ at risk volumes in conjunction with and as specified in dosimetry for three dimensional conformal radiotherapy of level 2 complexity.


All gross tumour targets, clinical targets, planning targets and organs at risk as defined in the prescription must be rendered as volumes. The organ at risk must be nominated as planning dose goals or constraints and the prescription must specify the organs at risk as dose goals or constraints. Dose volume histograms must be generated, approved and recorded with the plan. A CT image volume dataset must be used for the relevant region to be planned and treated. The CT images must be suitable for the generation of quality digitally reconstructed radiographic images



Fee: $1,138.70 Benefit: 75% = $854.05 85% = $1,054.00

(See para TN.2.3 of explanatory notes to this Category)

Category 5 - DIAGNOSTIC IMAGING SERVICES

61311

61311 - Additional Information

Item Start Date:
14-Sep-2019
Description Updated:
10-Jan-2020
Schedule Fee Updated:
14-Sep-2019

Group
I4 - Nuclear Medicine Imaging
Subgroup
1 - Nuclear medicine - non PET

Single stress or rest myocardial perfusion study—with PET (R)

Item 61311 was only available from 14 September 2019 until 20 December 2019, during a national shortage of technetium. See the Health Insurance (Section 3C Diagnostic Imaging - Nuclear Medicine Services) Amendment (No. 2) Determination 2019 on the Federal Register of Legislation for further information.

Bulk bill incentive



Fee: $565.30 Benefit: 75% = $424.00 85% = $480.60

Category 5 - DIAGNOSTIC IMAGING SERVICES

61332

61332 - Additional Information

Item Start Date:
14-Sep-2019
Description Updated:
10-Jan-2020
Schedule Fee Updated:
14-Sep-2019

Group
I4 - Nuclear Medicine Imaging
Subgroup
1 - Nuclear medicine - non PET

Combined stress and rest, stress and re‑injection or rest and redistribution myocardial perfusion study, including delayed imaging or re‑injection protocol on a subsequent occasion—with PET (R)

Item 61332 was only available from 14 September 2019 until 20 December 2019, during a national shortage of technetium. See the Health Insurance (Section 3C Diagnostic Imaging - Nuclear Medicine Services) Amendment (No. 2) Determination 2019 on the Federal Register of Legislation for further information.

Bulk bill incentive



Fee: $834.90 Benefit: 75% = $626.20 85% = $750.20

Category 5 - DIAGNOSTIC IMAGING SERVICES

61333

61333 - Additional Information

Item Start Date:
14-Sep-2019
Description Updated:
10-Jan-2020
Schedule Fee Updated:
14-Sep-2019

Group
I4 - Nuclear Medicine Imaging
Subgroup
1 - Nuclear medicine - non PET

Lung perfusion study and lung ventilation study using galligas or 68Ga-MAA, with PET (R)

Item 61333 was only available from 14 September 2019 until 20 December 2019, during a national shortage of technetium. See the Health Insurance (Section 3C Diagnostic Imaging - Nuclear Medicine Services) Amendment (No. 2) Determination 2019 on the Federal Register of Legislation for further information.

Bulk bill incentive



Fee: $443.35 Benefit: 75% = $332.55 85% = $376.85

Category 5 - DIAGNOSTIC IMAGING SERVICES

61336

61336 - Additional Information

Item Start Date:
14-Sep-2019
Description Updated:
10-Jan-2020
Schedule Fee Updated:
14-Sep-2019

Group
I4 - Nuclear Medicine Imaging
Subgroup
1 - Nuclear medicine - non PET

Cerebral perfusion study, with PET (R)

Item 61336 was only available from 14 September 2019 until 20 December 2019, during a national shortage of technetium. See the Health Insurance (Section 3C Diagnostic Imaging - Nuclear Medicine Services) Amendment (No. 2) Determination 2019 on the Federal Register of Legislation for further information.

Bulk bill incentive



Fee: $605.05 Benefit: 75% = $453.80 85% = $520.35

Results 1 to 10 of 34 matches


Legend

  • Assist - Addition/Deletion of (Assist.)
  • Amend - Amended Description
  • Anaes - Anaesthetic Values Amended
  • Emsn - EMSN Change
  • Fee - Fee Amended
  • Renum - Item Number Change (renumbered)
  • New - New Item
  • NewMin - New Item (previous Ministerial Determination)
  • Qfe - QFE Change